5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of multicenter trial)

The results of multicenter prospective trial for efficacy of combined modality treatment: transurethral resection (TUR) + photodynamic therapy (PDT) with alasens for bladder cancer are represented in the article. Trials were organized by Research Institute of Organic Intermediates and Dyes and conducted according to clinical protocol approved by Ministry of Health of Russia, at the sites of leading Russian cancer clinical centers. The trial included 45 subjects with verified diagnosis of non-muscle-invasive bladder cancer. Patients underwent TUR of bladder with simultaneous PDT as anti-relapse treatment. Alasens was administered to patients as intravesicular instillation of 3% solution in volume of 50ml with 1.5-2h exposure (prior to TUR). TUR was performed after instillation. PDT session was conducted immediately after the completion of TUR on a single occasion by means of combined local irradiation on tumor bed with diffuse irradiation on whole urinary bladder mucosa (light dose of local irradiation - 100J/cm2, diffuse irradiation - 20J/cm2). Good tolerance of the treatment was noticed, there were no complications. Among 45 patients included in the trial, 35 (78%) completed 12 month protocol follow-up without relapse. In our study PDT with alasens after TUR allowed to decrease the recurrence rate of non-muscle-invasive bladder cancer for 1st year after treatment to 22%. TUR with intraoperative PDT with 5-aminolevulinic acid may offer an alternative in the treatment of non-muscle-invasive intermediate and high-risk bladder cancer.

Photodiagnosis and photodynamic therapy. 2016 Sep 23 [Epub ahead of print]

E V Filonenko, A D Kaprin, B Y A Alekseev, O I Apolikhin, E K Slovokhodov, V I Ivanova-Radkevich, A N Urlova

P.A. Herzen Moscow Cancer Research Institute-the Branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia; The State Education Institution of Higher Professional Training, the First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation, Moscow, Russia. Electronic address: ., P.A. Herzen Moscow Cancer Research Institute-the Branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia., P.A. Herzen Moscow Cancer Research Institute-the Branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia; Research Institute of Urology, Moscow, Russia., Research Institute of Urology, Moscow, Russia., City clinical hospital #40, Moscow, Russia., Peoples' Friendship University of Russia, Moscow, Russia.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe